To compare the real-world persistence of ofatumumab vs platform self-injectable or oral disease-modifying therapies (DMTs).
No takes yet. Share an insight, caveat, or question.
Hersh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: